Compare Globus Medical Inc. Class A Common Stock (GMED) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Veritone Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Veritone Inc trades at $0.53 (market cap $59.95M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 171× Veritone Inc's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Veritone Inc for 13 Days on average.
| GMED | VERI | |
|---|---|---|
Market Cap | $10.25B | $59.95M |
Volume | 1,108,124 | 2,880,267 |
Sector | Health | Technology |
52-Week High | $96.82 | $8.39 |
52-Week Low | $58.33 | $0.53 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $9.76B | $95.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Veritone (VERI) trades at $0.59, down 2.64% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of $111.73M on $92.19M revenue in 2025, with negative cash flow from operations. Recent news includes a $15M equity offering and partnerships like the ATP Media deal, while facing a securities class action investigation.
The outlook remains challenged by persistent losses and cash burn, though analyst consensus is a Buy with a $3.75 price target. Key risks include execution on cost reductions, competitive pressures in AI, and legal overhangs. Upside hinges on revenue acceleration and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
